Icon

GLEEVEC (nda021335)- (EQ 50MG BASE,EQ 100MG BASE)

IMATINIB MESYLATE NOVARTIS
EQ 50MG BASE,EQ 100MG BASE
No No
2022-Jun-19 Expired
None None
None No
Gleevec (imatinib mesylate) is indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 50MG BASE ** ** - - -
EQ 100MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.